Biotech news for Tuesday, May 26, 2026, ranked by our 5-dimension investment framework — regulatory, technology, commercial, manufacturing, and narrative.
Jacques LOIC An expert panel of the EU drug regulator endorsed eight new medicines for approval this week, including new indications for Merck's ( MRK ) and AstraZeneca's cancer drugs Keytruda and Enhertu, as well as AbbVie’s ( ABBV ) hepatitis C therapy, Mavi…
Anavex Life Sciences ( AVXL ) said on Friday it received an expected delinquency notification letter from the Nasdaq on May 20, 2026, after failing to timely file its Form 10-Q for the quarter ended March 31, 2026, resulting in non-compliance with Nasdaq Listi…
Assembly Biosciences ( ASMB ) announced the pricing of an underwritten offering of about 3.36M common shares at $26.50 per share, along with pre-funded warrants to purchase up to 415,000 additional shares for certain investors. Assembly Biosciences expects the…
IvelinRadkov Shares of Biogen ( BIIB ) and Denali Therapeutics ( DNLI ) fell in the premarket on Friday after the companies announced a decision to discontinue the development of BIIB122, an experimental therapy for Parkinson’s disease, following a mid-stage t…
Biotech firm Zai Lab ( ZLAB ) announced that President and COO Josh Smiley is leaving the company immediately as part of a leadership shake-up to improve efficiency. This executive change comes at a crucial time for the company, as it prepares for
Wirestock/iStock via Getty Images Akari Therapeutics ( AKTX ) on Thursday announced promising preclinical data demonstrating that its lead cancer therapy, AKTX-101, shows strong synergistic tumor-killing activity when combined with KRAS inhibitors in pancreati…
Maddie Meyer/Getty Images News Moderna’s ( MRNA ) marketing application for its flu vaccine, mRNA-1010, will be reviewed by the FDA's independent experts next month, according to a federal notice posted on Thursday. The meeting of the FDA's Vaccines and Relate…
FabrikaCr Stock futures edged down Thursday while Treasuries rose after President Trump said the U.S. was ready to strike Iran if no peace deal was reached, even as he signaled he was willing to wait on further military action. Here are
Akari Therapeutics ( AKTX ) announced on Thursday the pricing of a private placement financing round, expecting to raise an aggregate of approximately $5.5M in gross proceeds. With these funds, the company will focus on advancing its lead ADC program utilizing…
Immix Biopharma ( IMMX ) has priced its offering of 16,778,524 shares at a price to the public of $8.94 per share. The gross proceeds to Immix from the offering, before deducting the underwriting discounts, commissions, and other offering expenses, are expecte…